Printer Friendly

US FDA grants priority review to Alnylam Pharmaceuticals' Givosiran.

M2 EQUITYBITES-August 7, 2019-US FDA grants priority review to Alnylam Pharmaceuticals' Givosiran


The US Food and Drug Administration (FDA) has granted priority review to United States-based Alnylam Pharmaceuticals' investigational RNAi therapeutic, Givosiran, intended for the treatment of acute hepatic porphyria (AHP), it was reported yesterday.

The product is to be administered subcutaneously and is aimed at aminolevulinic acid synthase 1.

According to Alnylam, monthly administration of the investigational RNAi therapeutic can potentially decrease induced liver ALAS1 levels in a sustained manner by a significant extent. Owing to this capability, the investigational RNAi therapeutic can decrease neurotoxic heme intermediates, aminolevulinic acid and porphobilinogen, towards normal levels.

Givosiran has been set an action date of 4 February 2020 by the FDA under the Prescription Drug User Fee Act (PDUFA).

((Comments on this story may be sent to

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Aug 7, 2019
Previous Article:Benelli launches Leoncino 500 in India.
Next Article:Glauconix Biosciences names new chief operating officer.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |